Next Article in Journal
Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity
Previous Article in Journal
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
Article

Specific Antibodies and Arachidonic Acid Mediate the Protection Induced by the Schistosoma mansoni Cysteine Peptidase-Based Vaccine in Mice

1
Zoology Department, Faculty of Science, Cairo University, Giza 12613, Egypt
2
Department of Chemistry, School of Science and Engineering, American University in Cairo, New Cairo 11835, Egypt
3
Zoology Department, Faculty of Science, Ein Shams University, Cairo 11566, Egypt
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 682; https://doi.org/10.3390/vaccines8040682
Received: 29 September 2020 / Revised: 29 October 2020 / Accepted: 4 November 2020 / Published: 16 November 2020
Several reports have documented the reproducible and considerable efficacy of the cysteine peptidase-based schistosomiasis vaccine in the protection of mice and hamsters against infection with Schistosoma mansoni and Schistosomahaematobium, respectively. Here, we attempt to identify and define the protection mechanism(s) of the vaccine in the outbred CD-1 mice-S. mansoni model. Mice were percutaneously exposed to S. mansoni cercariae following immunization twice with 0 or 10 μg S. mansoni recombinant cathepsin B1 (SmCB1) or L3 (SmCL3). They were examined at specified intervals post infection (pi) for the level of serum antibodies, uric acid, which amplifies type 2 immune responses and is an anti-oxidant, lipids, in particular, arachidonic acid (ARA), which is an endoschistosomicide and ovocide, as well as uric acid and ARA in the lung and liver. Memory IgG1, IgG2a, and IgG2b antibodies to the cysteine peptidase immunogen were detectable at and following day 17 pi. Serum, lung, and liver uric acid levels in immunized mice were higher than in naïve and unimmunized mice, likely as a consequence of cysteine peptidase-mediated catabolic activity. Increased circulating uric acid in cysteine peptidase-immunized mice was associated with elevation in the amount of ARA in lung and liver at every test interval, and in serum starting at day 17 pi. Together, the results suggest the collaboration of humoral antibodies and ARA schistosomicidal potential in the attrition of challenge S. mansoni (p < 0.0005) at the liver stage, and ARA direct parasite egg killing (p < 0.005). The anti-oxidant and reactive oxygen species-scavenger properties of uric acid may be responsible for the cysteine peptidase vaccine protection ceiling. This article represents a step towards clarifying the protection mechanism of the cysteine peptidase-based schistosomiasis vaccine. View Full-Text
Keywords: Schistosoma mansoni; cysteine peptidases; vaccine; humoral antibodies; uric acid; arachidonic acid Schistosoma mansoni; cysteine peptidases; vaccine; humoral antibodies; uric acid; arachidonic acid
Show Figures

Figure 1

MDPI and ACS Style

Tallima, H.; Abou El Dahab, M.; El Ridi, R. Specific Antibodies and Arachidonic Acid Mediate the Protection Induced by the Schistosoma mansoni Cysteine Peptidase-Based Vaccine in Mice. Vaccines 2020, 8, 682. https://doi.org/10.3390/vaccines8040682

AMA Style

Tallima H, Abou El Dahab M, El Ridi R. Specific Antibodies and Arachidonic Acid Mediate the Protection Induced by the Schistosoma mansoni Cysteine Peptidase-Based Vaccine in Mice. Vaccines. 2020; 8(4):682. https://doi.org/10.3390/vaccines8040682

Chicago/Turabian Style

Tallima, Hatem, Marwa Abou El Dahab, and Rashika El Ridi. 2020. "Specific Antibodies and Arachidonic Acid Mediate the Protection Induced by the Schistosoma mansoni Cysteine Peptidase-Based Vaccine in Mice" Vaccines 8, no. 4: 682. https://doi.org/10.3390/vaccines8040682

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop